DiFUSION Technologies, Inc., a medical device company targeting the orthopaedic market, today announced its corporate launch. The company will focus on reducing the rising incidence of Surgical Site Infections (SSIs) in spinal surgeries.
“In large studies, five out of 100 spine cases result in SSIs often leading to second surgeries that are extremely costly and difficult for the patient,” said Dr. Matthew Geck, founder and board member of DiFUSION and leading orthopaedic surgeon in Austin, Texas. “DiFUSION will release a medical device in 2009 capable of killing 650 types of bacteria including antibiotic-resistant bacteria such as MRSA (also known as “Superbugs”) in the local surgical wound for up to four weeks following surgery.”
DiFUSION’s founding and scientific board members comprise a team of recognized physicians in the field of spinal, biochemical and genetic research, and senior executives hold extensive experience in spinal product development and clinical studies.
“DiFUSION’s solution may not only improve infection ratios, the ‘super silicate’ technology will also affect the bone remodeling sequence in a potentially positive fashion,” said Dr. Peter Whang, a member of DiFUSION’s scientific advisory board and an Assistant Professor in the Department of Orthopaedics and Rehabilitation at the Yale University School of Medicine in New Haven, Connecticut. “SSIs are also a focus of quality improvement as part of the ‘pay for performance’ initiative for hospitals, insurers and physicians.”
“The controlled delivery of cationic elements possible with our ‘super silicate’ open multiple promising applications from infection control to bone growth,” said Dr. Gary Ghiselli, chair of the DiFUSION scientific advisory board and a board-certified orthopaedic surgeon in Denver, Colorado, who exclusively focuses on spine and complex deformity and degenerative disorders of the cervical spine. “Hospital born surgical site infections place a $5 billion annual burden on the U.S. health care system. Our technology has the potential to save $150 million in the spine segment alone, a tremendous savings for the health care industry.”
DiFUSION is funded by angel investors, and the company will be seeking a second round of funding for marketing and sales support in order to roll out the medical device on a nationwide basis. Current investors are expected to participate in the upcoming round.
About DiFUSION Technologies
DiFUSION Technologies, located in Austin, Texas, is a medical device company that develops silver-based antimicrobial solutions for the orthopaedic spinal market to reduce Surgical Site Infections (SSIs) in spinal surgery. DiFUSION will release a medical device in 2009 capable of mitigating 650 types of bacteria, including MRSA, up to four weeks postoperatively, thereby drastically reducing hospital acquired infections or SSIs. DiFUSION is funded by angel investors, and the company will be seeking a second round of funding for marketing and sales support in order to roll out the medical device on a nationwide basis. Current investors are expected to participate in the upcoming round. For more information about DiFUSION Technologies, visit www.difusiontech.com.
Source: DiFUSION Technologies, Inc.